FDA grants priority review to Teva’s ecopipam, potentially the first new Tourette treatment in over a decade

Teva’s experimental drug ecopipam, a novel dopamine D1 receptor blocker, has received FDA priority review, bringing hope for a new treatment for Tourette syndrome after more than 50 years since the last innovation. The US Food and Drug Administration has…















